Market Research Logo

Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

“Parkinson’s disease treatment market projected to grow at a CAGR of 6.1%”
The Parkinson’s disease treatment market is expected to grow from USD 4.24 billion in 2017 to USD 5,694.1 million in 2022 to grow at a CAGR of 6.1%. Factors such as the increasing aging population worldwide and government funding for research on Parkinson’s disease are driving this market. However, the availability of alternative treatments is expected to restrain this market.

“The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period”
On the basis of drug class, the Parkinson’s disease treatment market is classified into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest growth rate during the forecast period. The growth of this market segment is mainly driven by its potency and wide adoption in the treatment of Parkinson’s disease.

“The online pharmacies segment to grow at the fastest rate during the forecast period”
By distribution channel type, the Parkinson’s disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register highest CAGR during the forecast period. Advantages such as 24/7 ordering, home delivery, and discounts on medicines are the driving factors for this segment.

“Europe to hold the largest share of the regional market during the forecast period”
Geographically, the Parkinson’s disease treatment market is dominated by Europe, followed by North America, Asia, and the Rest of the World (RoW). Europe is expected to command the largest share of the Parkinson’s disease treatment market. The large share of this segment can be attributed to the growing aging population, presence of key players, and increasing healthcare expenditure in the region. The Asian region is estimated to grow at the fastest rate during the forecast period.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type - Tier 1 – 70% and Tier 2 – 30%
• By Designation – C-level – 62%, Director Level – 21%, Others – 17%
• By Region – North America – 50%, Europe – 20%, Asia – 30%

Key players operating in the Parkinson’s disease treatment market include Teva(Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddy’s (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India), Strides (India), 1 A Pharma (India), and Upsher-Smith (US).

Research Coverage:
The report analyses the Parkinson’s disease treatment market by drug class, distribution channel, patient care setting, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the report analyses developments and strategies adopted by key players to maintain and increase their shares in the market. The above-mentioned market research data, market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.

Benefits of Buying this Report:
This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.

The report provides insights on the following strategies:
• Market Penetration: The report analyzes the Parkinson’s disease treatment market by drug class, distribution channel, and patient care setting
• Competitive Assessment: In-depth assessment of the market strategies and geographic and business segments of the leading players in the Parkinson’s disease treatment market
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various drug classes across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the Parkinson’s disease treatment market


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
      • MARKETS COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • LIMITATIONS
    • STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • RESEARCH DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • MARKET SIZE ESTIMATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
    • Table GLOBAL PARKINSON'S DISEASE TREATMENT MARKET SUMMARY
  • PREMIUM INSIGHTS
    • PARKINSON'S DISEASE TREATMENT MARKET OVERVIEW
    • GEOGRAPHIC ANALYSIS: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS
    • GEOGRAPHIC ANALYSIS OF THE PARKINSON'S DISEASE TREATMENT MARKET, BY COUNTRY
    • GEOGRAPHIC ANALYSIS OF THE PARKINSON'S DISEASE TREATMENT MARKET
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • DRIVERS
        • Table AGEING POPULATION, BY REGION, 2015 VS 2030
      • RESTRAINTS
      • OPPORTUNITIES
        • Table PARKINSON'S DISEASE TREATMENT MARKET: LIST OF PIPELINE DRUGS
  • PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS
    • INTRODUCTION
      • Table PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2016-2022 (USD MILLION)
    • CARBIDOPA/LEVODOPA
      • Table CARBIDOPA/LEVODOPA MARKET, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: CARBIDOPA/LEVODOPA MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
    • DOPAMINE RECEPTOR AGONISTS
      • Table DOPAMINE RECEPTOR AGONISTS MARKET, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: DOPAMINE RECEPTOR AGONISTS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: DOPAMINE RECEPTOR AGONISTS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
    • MAO INHIBITORS
      • Table MAO INHIBITORS MARKET, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: MAO INHIBITORS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: MAO INHIBITORS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
    • COMT INHIBITORS
      • Table COMT INHIBITORS MARKET, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: COMT INHIBITORS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: COMT INHIBITORS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
    • ANTICHOLINERGICS
      • Table ANTICHOLINERGICS MARKET, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: ANTICHOLINERGICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: ANTICHOLINERGICS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
    • OTHER DRUGS
      • Table OTHER DRUGS MARKET, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: OTHER DRUGS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: OTHER DRUGS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
    • INTRODUCTION
      • Table PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
    • HOSPITAL PHARMACIES
      • Table PARKINSON'S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2015-2022 (USD MILLION)
    • RETAILER PHARMACIES
      • Table PARKINSON'S DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET FOR RETAILER PHARMACIES, BY COUNTRY, 2015-2022 (USD MILLION)
    • ONLINE PHARMACIES
      • Table PARKINSON'S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING
    • INTRODUCTION
      • Table PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
    • HOSPITALS
      • Table PARKINSON'S DISEASE TREATMENT MARKET FOR HOSPITALS, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: PARKINSON'S DISEASE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2015-2022 (USD MILLION)
    • CLINICS
      • Table PARKINSON'S DISEASE TREATMENT MARKET FOR CLINICS, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: PARKINSON'S DISEASE TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • PARKINSON'S DISEASE TREATMENT MARKET, BY REGION
    • INTRODUCTION
      • Table GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY REGION, 2015-2022 (USD MILLION)
    • EUROPE
      • Table EUROPE: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
      • Table EUROPE: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
      • Table EUROPE: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
      • U.S.
        • Table US: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
        • Table US: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
        • Table US: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
      • CANADA
        • Table CANADA: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
        • Table CANADA: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
        • Table CANADA: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
    • ASIA
      • Table ASIA: PARKINSON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
      • Table ASIA: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
      • Table ASIA: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
      • JAPAN
        • Table JAPAN: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
        • Table JAPAN: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
        • Table JAPAN: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
      • CHINA
        • Table CHINA: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
        • Table CHINA: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
        • Table CHINA: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
      • REST OF ASIA
        • Table ROA: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
        • Table ROA: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
        • Table ROA: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
    • REST OF THE WORLD
      • Table ROW: PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2015-2022 (USD MILLION)
      • Table ROW: PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2015-2022 (USD MILLION)
      • Table ROW: PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING, 2015-2022 (USD MILLION)
  • COMPANY PROFILES
    • GSK
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
    • MERCK
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
    • NOVARTIS
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
    • TEVA
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
    • BOEHRINGER INGELHEIM
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
    • IMPAX
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
    • ABBVIE
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
    • VALEANT PHARMACEUTICALS
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
    • LUNDBECK
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
    • SUN PHARMA
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
    • WOCKHARDT
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
    • ACADIA
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
    • UCB
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS
  • APPENDIX
    • INSIGHTS OF INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report